FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1041-1043 September 30, 1993 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Nabulsi, A. A. PubMed Citation

To the Editor: Nabulsi et al. (April 15 issue)¹ present convincing data that postmenopausal hormone-replacement therapy, whether with estrogen alone or with estrogen and progestin, greatly decreases the risk of cardiovascular disease. In their editorial, Martin and Freeman reiterate what has become almost conventional wisdom -- namely, that replacement therapy with progestins "attenuates [the] beneficial effects of estrogen on lipid levels" and therefore, presumably, may weaken the protective effect of estrogen-replacement therapy against cardiovascular disease². I should like to cite a number of studies that offer reassurance that progestins probably do not have such a deleterious effect. Two recent . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Galbiati, E., Caruso, P. L., Amari, G., Armani, E., Ghirardi, S., Delcanale, M., Civelli, M. (2002). . J. Pharmacol. Exp. Ther. 300: 802-809 [Abstract] [Full Text]  
• McDonnell, D. P., Connor, C. E., Wijayaratne, A., Chang, C.-y., Norris, J. D. (2002). Definition of the Molecular and Cellular Mechanisms Underlying the Tissue-selective Agonist/Antagonist Activities of Selective Estrogen Receptor Modulators. Recent Prog Horm Res 57: 295-316 [Abstract] [Full Text]